auto

China smartphone maker Xiaomi to invest $10 billion in new EV unit over 10 years


Globe Newswire

Global Head Mounted Display Market to Reach $98.4 Billion by 2027

Project Details: – StrategyR – A Trademark of Global Industry Analysts, Inc. – Project Edition: 8. – Influencer Pool: 7273. – MarketGlass™ Platform – Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.New York, March 30, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global General Anesthesia Drugs Industry” – https://www.reportlinker.com/p06041412/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. – Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors – Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.Mobile Access & App – Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.Complimentary Updates – for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.Bespoke Updates & Team Collaborations – Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center – clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: – Global General Anesthesia Drugs Market to Reach $5.1 Billion by 2027 – Amid the COVID-19 crisis, the global market for General Anesthesia Drugs estimated at US$4.4 Billion in the year 2020, is projected to reach a revised size of US$5.1 Billion by 2027, growing at a CAGR of 2.2% over the analysis period 2020-2027. Propofol, one of the segments analyzed in the report, is projected to record a 2.2% CAGR and reach US$1.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Sevoflurane segment is readjusted to a revised 2.1% CAGR for the next 7-year period. – The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 4.3% CAGR – The General Anesthesia Drugs market in the U.S. is estimated at US$1.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2027 trailing a CAGR of 4.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.5% and 1.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1% CAGR. – Desflurane Segment to Record 1.7% CAGR – In the global Desflurane segment, USA, Canada, Japan, China and Europe will drive the 1.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$363.3 Million in the year 2020 will reach a projected size of US$400.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$697.1 Million by the year 2027, while Latin America will expand at a 2.5% CAGR through the analysis period. – Select Competitors (Total 43 Featured) – Abbott LaboratoriesAstraZeneca PLCBaxter International, Inc.Eisai Co., Ltd.F. Hoffmann-La Roche AGFresenius SE & Co. KGaAHikma Pharmaceuticals PLCHospira, Inc.Novartis AGPfizer, Inc. Read the full report: https://www.reportlinker.com/p06041412/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for General Anesthesia Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for General Anesthesia Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for General Anesthesia Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Propofol by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Propofol by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Propofol by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Sevoflurane by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Sevoflurane by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Sevoflurane by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Desflurane by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Desflurane by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Desflurane by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Isoflurane by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Isoflurane by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Isoflurane by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Dexmedetomidine by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Dexmedetomidine by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Dexmedetomidine by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Remifentanil by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Remifentanil by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Remifentanil by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Midazolam by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Midazolam by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Midazolam by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 25: World Current & Future Analysis for Other Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 26: World Historic Review for Other Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: World 15-Year Perspective for Other Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 28: World Current & Future Analysis for Inhalation by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 29: World Historic Review for Inhalation by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: World 15-Year Perspective for Inhalation by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 31: World Current & Future Analysis for Injection by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 32: World Historic Review for Injection by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: World 15-Year Perspective for Injection by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 34: USA Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: USA Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: USA 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 37: USA Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: USA Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: USA 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 CANADA Table 40: Canada Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: Canada Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: Canada 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 43: Canada Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: Canada Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: Canada 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 JAPAN Table 46: Japan Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: Japan Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: Japan 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 49: Japan Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 50: Japan Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Japan 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 CHINA Table 52: China Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: China Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: China 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 55: China Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: China Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: China 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 EUROPE Table 58: Europe Current & Future Analysis for General Anesthesia Drugs by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 59: Europe Historic Review for General Anesthesia Drugs by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: Europe 15-Year Perspective for General Anesthesia Drugs by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 61: Europe Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: Europe Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: Europe 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 64: Europe Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Europe Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Europe 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 FRANCE Table 67: France Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: France Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: France 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 70: France Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: France Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: France 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 GERMANY Table 73: Germany Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: Germany Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: Germany 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 76: Germany Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: Germany Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: Germany 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 ITALY Table 79: Italy Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: Italy Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: Italy 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 82: Italy Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Italy Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Italy 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 85: UK Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: UK Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: UK 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 88: UK Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: UK Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: UK 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 SPAIN Table 91: Spain Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Spain Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Spain 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 94: Spain Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: Spain Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Spain 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 RUSSIA Table 97: Russia Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Russia Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Russia 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 100: Russia Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 101: Russia Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Russia 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 REST OF EUROPE Table 103: Rest of Europe Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Rest of Europe Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Rest of Europe 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 106: Rest of Europe Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Rest of Europe Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Rest of Europe 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 109: Asia-Pacific Current & Future Analysis for General Anesthesia Drugs by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 110: Asia-Pacific Historic Review for General Anesthesia Drugs by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: Asia-Pacific 15-Year Perspective for General Anesthesia Drugs by Geographic Region – Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 112: Asia-Pacific Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: Asia-Pacific Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: Asia-Pacific 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 115: Asia-Pacific Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: Asia-Pacific Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: Asia-Pacific 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 AUSTRALIA Table 118: Australia Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: Australia Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: Australia 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 121: Australia Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: Australia Historic Review for General Anesthesia Drugs by Route Of Administration – Inhalation and Injection Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 123: Australia 15-Year Perspective for General Anesthesia Drugs by Route Of Administration – Percentage Breakdown of Value Sales for Inhalation and Injection for the Years 2012, 2020 & 2027 INDIA Table 124: India Current & Future Analysis for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 125: India Historic Review for General Anesthesia Drugs by Drugs – Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 126: India 15-Year Perspective for General Anesthesia Drugs by Drugs – Percentage Breakdown of Value Sales for Propofol, Sevoflurane, Desflurane, Isoflurane, Dexmedetomidine, Remifentanil, Midazolam and Other Drugs for the Years 2012, 2020 & 2027 Table 127: India Current & Future Analysis for General Anesthesia Drugs by Route Of Administration – Inhalation and Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06041412/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.  Learn more